Heartseed
Heartseed is dedicated to transforming the treatment of severe heart failure through innovative regenerative medicine. Founded in 2015, the company focuses on developing therapies using iPS cells to generate cardiomyocytes for transplantation, aiming to open new doors in cardiovascular disease treatment worldwide.
Industries
Nr. of Employees
small (1-50)
Heartseed
Seavans South Building 5F, 1-2-3 Shibaura, Minato-ku, Tokyo 105-0023, JAPAN
Patents
Method of constructing masses of myocardial cells and use of the myocardial cell mass
US-10918671-B2
View DetailsMethod for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
US-9115342-B2
View DetailsMethod of constructing masses of myocardial cells and use of the myocardial cell mass
US-9109205-B2
View Details
Method of constructing masses of myocardial cells and use of the myocardial cell mass
US-10918671-B2
View DetailsMethod for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
US-9115342-B2
View DetailsMethod of constructing masses of myocardial cells and use of the myocardial cell mass
US-9109205-B2
View DetailsProducts
HS-001 (investigational allogeneic iPSC-derived cardiomyocyte therapy)
An investigational allogeneic iPSC-derived cardiomyocyte product developed for transplantation into failing myocardium to restore contractile function in patients with heart failure with reduced ejection fraction.
HS-001 (investigational allogeneic iPSC-derived cardiomyocyte therapy)
An investigational allogeneic iPSC-derived cardiomyocyte product developed for transplantation into failing myocardium to restore contractile function in patients with heart failure with reduced ejection fraction.
Services
Organizing and conducting early-phase clinical studies of iPSC-derived cardiomyocyte therapeutics, including protocol implementation and patient enrollment.
Joint research with external partners to develop more convenient intramyocardial delivery methods and more efficient iPSC production processes.
Organizing and conducting early-phase clinical studies of iPSC-derived cardiomyocyte therapeutics, including protocol implementation and patient enrollment.
Joint research with external partners to develop more convenient intramyocardial delivery methods and more efficient iPSC production processes.
Expertise Areas
- Cardiac regenerative medicine
- iPSC-derived cell therapy development
- Preclinical and early-phase clinical development
- CMC and GMP manufacturing planning for biologics
Key Technologies
- Induced pluripotent stem cell (iPSC) differentiation
- Cardiomyocyte spheroid (microtissue) fabrication
- Cell purification and differentiation processes
- Intramyocardial injection delivery
News & Updates
Heartseed was featured on CNN’s 'Tomorrow Transformed' on October 8, 2024.
Heartseed was featured on NHK World's CATCH JAPAN on July 19, 2021.
A feature on stem cell innovations including Heartseed, published on July 19, 2021.
A feature on stem cell innovations including Heartseed.
Recognition for Heartseed as Healthcare Company of the Year 2020.
Interview with CEO Keiichi Fukuda on BS Fuji.
Heartseed was featured on CNN’s 'Tomorrow Transformed' on October 8, 2024.
Heartseed was featured on NHK World's CATCH JAPAN on July 19, 2021.
A feature on stem cell innovations including Heartseed, published on July 19, 2021.
A feature on stem cell innovations including Heartseed.
Recognition for Heartseed as Healthcare Company of the Year 2020.
Interview with CEO Keiichi Fukuda on BS Fuji.